-

Company Profile for Axcella Health Inc.

--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.

Company:

Axcella Health Inc.

 

 

Headquarters Address:

840 Memorial Dr., Third Floor

 

CAMBRIDGE, MA 02139

 

 

Main Telephone:

857-320-2200

 

 

Website:

www.axcellahealth.com

 

 

Ticker:

AXLA(NASDAQ)

 

 

Type of Organization:

Public

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Bill Hinshaw

 

 

Investor Relations

 

Contact:

Jason Fredette

Phone:

7814240946

Email:

jfredette@axcellahealth.com

 

Industry:

Axcella Health Inc.

NASDAQ:AXLA
Details
Headquarters: Cambridge, MA
CEO: William Hinshaw, Jr.
Employees: 60
Organization: PUB
Release Versions
English
More News From Axcella Health Inc.

Axcella Announces Reverse Stock Split Effective September 19, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Na...

Axcella Granted Patent for Long COVID Fatigue Treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long CO...

Axcella Reports Second Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. “Patients are seeking relief from Long COVID fatigue. Axcella’s proprietary composition of amino acids in AXA1125 in Long COVID fatigue i...
Back to Newsroom